Evaluation of antidepressant and anxiolytic activity of phosphodiesterase 3 inhibitor-Cilostazol

Indian Journal of Psychological Medicine

Volumn 34, Issue 2, 2012, Pages 124-128

  Patel, Dipesh S ^b   Anand, Indermeet Singh ^b   Bhatt, Parloop A ^a  

^a L M COLLEGE OF PHARMACY   (India)

^b Shri Sarvajanik Pharmacy College   (India)

Author keywords

Cilostazol; Forced swim test; Marble burying behavior model; PDE3 inhibitor; Tail suspension test

Indexed keywords

EID: 84867340898     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.101776     Document Type: Article

References (32)

1. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305-15
2. Frasure-Smith N, Lesperance F, Habra M, Talajic M, Khairy P, Dorian P, et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation 2009;120:134-40
3. Lett H, Ali S, Whooley M. Depression and Cardiac Function in Patients with Stable Coronary Heart Disease: Findings from the Heart and Soul Study. Psychosom Med 2008; 70:444-9
4. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9
5. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86
6. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (Pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovascular Drug Review. 2001;19:369-86
7. Nandhakumar J, Raja AK, Tyagi MG. Characterization of effects of phosphodiesterase (PDE) isozyme inhibitors in animal models of epilepsy. Life Sci Med Res 2010;1-9
8. Lee JH, Kim KY, lee YK, Park SY, Kim CD, Lee WS, et al. Cilostazol Prevents Focal Cerebral Ischemic Injury by Enhancing Casein Kinase 2 Phosphorylation and Suppression of Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation in rats. J Pharmacol Experiment Thera 2004;308:896-903
9. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006;37:1539-45
10. Zhao J, Harada N, Kurihara H, Nakagata N, Okajima K. Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. Neuropharmacology 2009;58:774-83
11. Hebb AL, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 2007;7:86-92
12. Houslay MD, Schafer P, Zhang YJ. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-19
13. Houslay MD, Baillie GS, Maurice DH. cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007;100:950-66
14. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25:158-63
15. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002;27:587-95
16. Maxwell CR, Kanes SJ, Abel T, Siegel SJ. Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications. Neuroscience 2004;129:101-7
17. Campbell E, Edwards T. Zaprinast consolidates long-term memory when administered to neonate chicks trained using a weakly reinforced single trial passive avoidance task. Behav Brain Res 2006;169:181-5
18. Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol 2004;498:135-42
19. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007;8:54-9
20. Nishimura K, Ishigooka J, Imamura Y, Ihara S. Cilostazol, a cAMP Phosphodiesterase 3 Inhibitor in the Treatment of Poststroke Depression. J Neuropsychiatry Clin Neurosci 2007;19:471-2
21. Kalra BS, Tayal V, Chawla S. Antidepressant like activity of tramadol in mice. Indian J Psychiatry 2008;50:51-3
22. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985;85:367-70
23. Santosh P, Venugopal R, Nilakash AS, Kunjbihari S, Mangala L. Antidepressant activity of methanolic extract of passiflora foetida leaves in mice. Int J Pharm Pharm Sci 2011;3:112-5
24. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2
25. Rahman H, Muralidharan P, Sivaraman D, Kartika B, Saha D. Evaluation of anxiolytic activity of ethanolic extracts from the leaves of Trichosanthes cucumerina L. in mice. Der Pharmacia Sinica. 2010;1:86-94
26. Njunge K, Handley SL. Evaluation of Marble-Burying Behavior as a Model of Anxiety, Pharmacology Biochemistry and Behavior 1991;38:63-7
27. Patient information leaflet. Available from: http://www. cipladoc.com/therapeutic/pdf-cipla/pletoz.pdf, updated on May 2010. [Assessed on 2010 Dec 15].
28. Badhe SR, Badhe RV, Ghaisas MM, Chopade VV, Deshpande AD. Evaluations of antidepressant activity of Anacyclus pyrethrum root extract. Int J Green Pharm 2010;4:79-82
29. Bhatt PA, Patel DS, Anand IS, Shah UG, Patel SB. Antidepressant Activity of Phosphodiesterase 3 Inhibitor: Cilostazol. Int J Pharm Clin Res 2011;3:52-4
30. Roach SS. Introduction to clinical pharmacology and Drug Guide, 7th ed., (Visible Productions LLC) © 2004 ISBN: 0-7817-3696-X, © 2003 ISBN: 0-7817-1751-5. NY: Lippincott Williams and Wilkins; 2007
31. Homma C, Yamada K. Physical Properties of Bedding Materials Determine the Marble Burying Behavior of Mice (C57BL/6J). Open Behav Sci J 2009;3:34-9
32. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009; 198:366-71